PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
PF-07104091 as a Single Agent and in Combination Therapy
- Conditions
- Breast CancerSmall Cell Lung CancerOvarian Cancer
- Interventions
- Drug: PF-07104091 monotherapy dose escalationDrug: PF-0704091 + Fulvestrant (post CDK4/6)Drug: PF-07104091 + palbociclib + fulvestrantDrug: PF-07104091 + palbociclib + letrozoleDrug: PF-07104091 monotherapy dose expansion (SCLC)Drug: PF-07104091 monotherapy dose expansion (ovarian)Drug: PF-07104091 + Fulvestrant (post CDK4/6)
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 154
- Registration Number
- NCT04553133
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT04552470
- Locations
- 🇯🇵
P-one clinic, Keikokai medical corporation, Hachioji, Tokyo, Japan
Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed Condition
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT04549480
- Locations
- 🇳🇱
PRA Health Sciences Utrecht, Utrecht, Netherlands
🇳🇱PRA Health Sciences, Groningen, Netherlands
Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis
- Conditions
- Invasive AspergillosisMucormycosis
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 307
- Registration Number
- NCT04550936
- Locations
- 🇫🇷
Hôpital Huriez CHU de Lille, Lille, France
🇫🇷Institut de Cancérologie, Strasbourg, France
🇫🇷CHU de Limoges, Limoges, France
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 20-valent pneumococcal conjugate vaccineBiological: 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1258
- Registration Number
- NCT04546425
- Locations
- 🇦🇺
Perth Children's Hospital, Nedlands, Western Australia, Australia
🇦🇺Telethon Kids Institute, Vaccine Trials Group, Perth Children's Hospital, Nedlands, Western Australia, Australia
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.
- Conditions
- Household Contacts
- Interventions
- Other: Blood Draw
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT04543357
- Locations
- 🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
- Conditions
- Brain Neoplasms, PrimaryMalignant NeoplasmsMalignant MelanomaBrain NeoplasmsCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT04543188
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT04543344
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT04541706
- Locations
- 🇮🇳
Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India
🇮🇳The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
🇮🇳Apex Wellness Hospital, Nashik, Maharashtra, India
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT04535167
- Locations
- 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸Massachusetts General Hospital Translational and Clinical Research Center, Boston, Massachusetts, United States
🇧🇪University Hospital Brugmann, Brussels, Belgium